PD-L1 Antibody SHR-1316
Phase 2Small molecule
PD-L1 Antibody SHR-1316 is one of 37 small molecule programs targeting Intrahepatic Cholangiocarcinoma. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
44 competitors in Intrahepatic Cholangiocarcinoma
#DrugCompanyPhaseTrials
1Lenvima
EisaiApproved
Alkeran
AApotex Inc.
Approved
Velcade
SShilpa Grover, MD, MPH
Approved
Paraplatin
AAvyxa
Approved
Gemzar
Johnson & JohnsonPhase 2
Imfinzi
AstraZenecaPhase 2
Beyfortus
BeiGenePhase 2
Eloxatin
TevaPhase 2
Fudr
PfizerPhase 2
Pemazyre
IncytePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Esophageal Squamous Cell Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PD-L1 Antibody SHR-1316. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SShanghai Zhongshan Hospital